The activity of both, cytosolic (TK1) and mitochondrial thymidine kinase (TK2), is upregulated by anti-cancer agents targeting thymidine synthase (TS) in the pyrimidine de novo synthesis pathways. The gene discussed is TYMS; the disease is cancer.